title: Penta-O-galloyl-β-D-glucose suppresses EGF-induced eIF3i expression through inhibition of the PI3K/AKT/mTOR pathway in prostate cancer cells.
abstract: Approximately 70% of prostate cancer patients will develop bone metastasis in axial and other regions of the skeleton. Epidermal growth factor (EGF) generated from bone tissue contributes to prostate cancer metastasis. In a previous study, penta-O-galloyl-β-D-glucose (PGG) suppressed androgen-independent prostate cancer bone metastasis by transcriptionally repressing EGF-induced MMP-9 expression. This study utilized proteomics to analyze the effects of PGG in EGF-induced prostate cancer bone metastasis. This study showed that PGG suppressed EGF-induced eIF3i expression in PC-3 cells. By transfection of eIF3i shRNA, it was observed that reduced eIF3i expression suppressed the invasion of PC-3 cells in vitro. PGG reduced EGF-induced eIF3i expression through inhibition of the PI3K/AKT/mTOR pathway. Therefore, PGG may be able to be used as a potential new therapeutic drug for prostate cancer bone metastasis.
authors.affiliation: Department of Urology, E-Da Hospital, I-Shou University , Kaohsiung, Taiwan.
authors.forename: Victor Chia-Hsiang
authors.initials: VC
authors.lastname: Lin
authors.forename: Po-Tsun
authors.initials: PT
authors.lastname: Kuo
authors.forename: Ying-Chao
authors.initials: YC
authors.lastname: Lin
authors.forename: Yeh
authors.initials: Y
authors.lastname: Chen
authors.forename: You-Cheng
authors.initials: YC
authors.lastname: Hseu
authors.forename: Hsin-Ling
authors.initials: HL
authors.lastname: Yang
authors.forename: Jung-Yie
authors.initials: JY
authors.lastname: Kao
authors.forename: Chi-Tang
authors.initials: CT
authors.lastname: Ho
authors.forename: Tzong-Der
authors.initials: TD
authors.lastname: Way
mesh_terms: D001859:Bone Neoplasms / Q000517:prevention & control / Q000556:secondary; D045744:Cell Line, Tumor; D004815:Epidermal Growth Factor / Q000494:pharmacology; D039621:Eukaryotic Initiation Factor-3 / Q000235:genetics*; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D047348:Hydrolyzable Tannins / Q000494:pharmacology*; D008297:Male; D009362:Neoplasm Metastasis / Q000517:prevention & control; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011471:Prostatic Neoplasms / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors*; D034741:RNA, Small Interfering / Q000235:genetics; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D014162:Transfection
chemical_list: D039621:Eukaryotic Initiation Factor-3; D047348:Hydrolyzable Tannins; D000081082:Phosphoinositide-3 Kinase Inhibitors; D034741:RNA, Small Interfering; C096013:EIF3I protein, human; C435084:pentagalloylglucose; D004815:Epidermal Growth Factor; C546842:MTOR protein, human; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases
keywords: EGF; PGG; PI3K/AKT/mTOR; bone metastasis; prostate cancer